Augmentin Dose for UTI
For uncomplicated cystitis in adults, amoxicillin-clavulanate 875/125 mg twice daily for 3-7 days is appropriate when other first-line agents cannot be used, though it is not a preferred first-line choice due to inferior efficacy and more adverse effects compared to nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin 1.
Dosing by Clinical Scenario
Uncomplicated Cystitis (Adults)
- Standard dose: Amoxicillin-clavulanate 875/125 mg orally twice daily for 3-7 days 1
- Alternative: 500/125 mg three times daily 2
- β-lactams including amoxicillin-clavulanate are considered second-line agents for uncomplicated cystitis because they demonstrate inferior efficacy and higher adverse effect rates compared to nitrofurantoin (5 days), TMP-SMX (3 days), or fosfomycin (single dose) 1, 3
- Use only when first-line agents are contraindicated or unavailable 1
Uncomplicated Pyelonephritis (Adults)
- Amoxicillin-clavulanate is not recommended as empiric therapy for pyelonephritis 4
- Insufficient data support oral β-lactams for pyelonephritis treatment 3
- Preferred agents: fluoroquinolones (5-7 days) or TMP-SMX (14 days) based on local susceptibility 3, 5
Pediatric UTI (Ages 3 months and older)
- AUGMENTIN ES-600: 90 mg/kg/day (based on amoxicillin component) divided every 12 hours for 10 days 6
- Standard formulations: 20-40 mg/kg/day in 3 divided doses 2
- For febrile UTI in children 2-24 months: 7-14 days total duration 2
Important Clinical Considerations
When Augmentin May Be Appropriate
Resistant organisms: High-dose amoxicillin-clavulanate (2875 mg amoxicillin/125 mg clavulanate twice daily) shows promise for ESBL-producing organisms in select cases, though this is not standard practice 7. This represents an emerging alternative to carbapenems for specific resistant UTIs.
Step-down therapy: After initial IV antibiotics for ESBL-producing E. coli UTI, switching to oral amoxicillin-clavulanate may be effective when susceptibility testing supports this choice 8.
Critical Limitations
The 2011 IDSA/ESCMID guidelines explicitly state that β-lactams have inferior efficacy compared to other UTI antimicrobials 1. This is a crucial consideration—amoxicillin-clavulanate should not be your first choice for empiric UTI treatment.
Local resistance matters: The decision to use amoxicillin-clavulanate must be guided by local antimicrobial susceptibility patterns. Many E. coli strains demonstrate resistance to β-lactams 1.
Common Pitfalls to Avoid
- Do not use plain amoxicillin or ampicillin for empiric UTI treatment due to very high worldwide resistance rates 1
- Do not substitute different Augmentin formulations interchangeably—they contain different amounts of clavulanic acid 6
- Do not use for pyelonephritis as first-line empiric therapy 4
- Gastrointestinal adverse effects are common, occurring in approximately 10-20% of patients 9, 10, 11
Administration Details
- Take at the start of meals to minimize GI intolerance and enhance clavulanate absorption 6
- Reconstituted suspension stable for 10 days under refrigeration 6
- Shake suspension well before each use 6
Duration of Therapy
- Uncomplicated cystitis: 3-7 days 1, 5
- Pediatric febrile UTI: 7-14 days 2
- Recurrent UTI: May require longer courses (up to 3 months prophylaxis in specialized cases) 7
The evidence consistently positions amoxicillin-clavulanate as a reserve agent for UTI treatment, appropriate when first-line options are unsuitable due to allergy, resistance, or intolerance 1, 4.